Knopp brings extensive capabilities in preclinical development, clinical development, regulatory strategy, and business operations to compelling programs. We currently seek to leverage these capabilities through licensing and other partnering opportunities fulfilling the following criteria:
- Therapeutic areas: Immunological, neurological, and neurodegenerative disorders with high unmet needs
- Stage: Optimized, lead molecules ready for IND-enabling studies through Phase 1 clinical development
- Class: Small molecules
- Exclusivity: Clear regulatory or composition-of-matter protection
If you’re seeking a partner to advance an opportunity meeting these criteria, don’t hesitate to let Knopp know at firstname.lastname@example.org.